eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | central retinal vein occlusion |
| Comorbidity | C0271051|macular oedema |
| Sentences | 9 |
| PubMedID- 20494908 | Purpose: to evaluate the efficacy and safety of simultaneous intravitreal injection of triamcinolone acetonide (ta) and tissue plasminogen activator (tpa) for macular oedema associated with central retinal vein occlusion (crvo). |
| PubMedID- 19696805 | Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. |
| PubMedID- 26149584 | Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study. |
| PubMedID- 21109696 | Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. |
| PubMedID- 25619682 | Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study. |
| PubMedID- 24513867 | Objectives: to review systematically the randomised controlled trial (rct) evidence for treatment of macular oedema due to central retinal vein occlusion (crvo). |
| PubMedID- 19563372 | Purpose: this study aimed to investigate whether vascular endothelial growth factor (vegf) or interleukin-6 (il-6) influence macular oedema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 22863290 | Macular hole after injection of dexamethasone intravitreal implant for macular oedema due to central retinal vein occlusion. |
| PubMedID- 20339391 | Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. |
Page: 1